Melanoma-Global Drug Forecast and Market Analysis to 2026

Latest industry research report on: Drug Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts.

Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure.

Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy, Imlygic (talimogene laherparepvec, Amgen). BRAF and MEK inhibitors were also first introduced to the market in 2011 (Novartiss Tafinlar [dabrafenib] + Mekinist [trametinib] and Roches Zelboraf [vemurafenib] + Cotellic [cobimetinib]). Together, these new MOAs provide renewed hope to improve the treatment outcomes of melanoma patients. These agents will be utilized in early lines of metastatic therapy, and will continue to push the use of chemotherapy to later treatment lines. Although these new treatments have extended the survival of metastatic patients compared with chemotherapy-only regimens, high unmet needs remain for the non-responders to these targeted treatments, especially in BRAF WT patients who are ineligible for BRAF/MEK targeted therapies. A number of promising pipeline products, especially immune checkpoint inhibitors in combinations, will likely change the treatment landscape in the next few years.

Complete Report Details @ https://www.marketresearchreports.biz/reports/1471772/pharmapoint-melanoma-global-drug-forecast-and-market-research-reports

Scope

- Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

- Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments, forecast from 2016 to 2026.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market.

- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for melanoma. The most promising candidates in Phase III development are profiled.

- Analysis of the current and future market competition in the global melanoma market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/1471772

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global melanoma market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Have Any Query? Ask Our Expert @ https://www.marketresearchreports.biz/sample/enquiryBuy/1471772

Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 10

2 Executive Summary 12

2.1 Modest Growth in the Melanoma Market Expected from 2016-2026 12

2.2 Despite Strong Competition, Bristol-Myers Squibb to Remain the Leader of the Checkpoint Immunotherapy and Overall Melanoma Market 15

2.3 High Unmet Need Remains for Efficacious Treatment Options in BRAF Wild-Type Patients 17

2.4 High Commercial Opportunity for Adjuvant Treatments that Improve Cure Rates in Early-Stage, Resectable Melanoma Patients 17

2.5 Innovative Immune Checkpoint Inhibitor Combinations Strive for Market Penetration Due to a Crowded Melanoma Market 18

2.6 Late-Stage Pipeline Agents to Have Limited Impact on the Future Melanoma Landscape 18

2.7 What Do the Physicians Think? 20

3 Introduction 21

3.1 Catalyst 21

3.2 Related Reports 22

3.3 Upcoming Related Reports 22

4 Disease Overview 23

4.1 Etiology and Pathophysiology 23

4.1.1 Etiology 23

4.1.2 Pathophysiology 24

4.1.3 Melanoma Biomarkers 24

4.2 Clinical Staging 26

4.3 Symptoms 29

4.4 Prognosis 29

4.5 Quality of Life 31

5 Epidemiology 32

5.1 Disease Background 32

5.2 Risk Factors and Comorbidities 32

5.3 Global and Historical Trends 34

5.4 Forecast Methodology 37

5.4.1 Sources Used 38

5.4.2 Forecast Assumptions and Methods 41

5.5 Epidemiological Forecast for Melanoma (2016-2026) 46

5.5.1 Diagnosed Incident Cases of Melanoma 46

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact Us

State Tower

90 State Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

This release was published on openPR.